Importance of antibodies to the fusion glycoprotein of paramyxoviruses in the prevention of spread of infection by unknown
IMPORTANCE  OF  ANTIBODIES  TO  THE  FUSION 
GLYCOPROTEIN  OF  PARAMYXOVIRUSES 
IN  THE  PREVENTION  OF  SPREAD  OF  INFECTION* 
BY DAVID CHARLES MERZ,:~ ANDREAS SCHEID, ANt) PURNELL W. CHOPPIN 
From  The Rockefeller University, New  York 10021 
Paramyxoviruses comprise a  large  family of enveloped  RNA viruses  that  include 
the parainfluenza, mumps, measles, and respiratory syncytial viruses (1). These viruses 
cause a  variety of diseases, ranging in severity from mild upper respiratory infections 
to  bronchiolitis,  pneumonia,  and  encephalitis.  They  can  also  establish  persistent 
infections (2, 3)  that can lead to chronic disease, e.g., subacute sclerosing panenceph- 
alitis caused by measles virus (4). In spite of the importance of these diseases, effective 
live virus vaccines are available for only two of the human paramyxovirus infections, 
measles  and  mumps,  and  inactivated  vaccines have been  ineffective or have  led  to 
complications, as will be discussed below. 
Two glycoproteins are found on the surface of paramyxoviruses (5) and are involved 
in  the  generation  of immunity  to  infection.  The  HN 1 protein  is  responsible  for 
hemagglutinating  and  neuraminidase  activities  and  for  adsorption  of the  virus  to 
receptors on host cells (6). The F protein is involved in the cell-fusing and hemolyzing 
activities of the virus, and in virus penetration by fusion of viral and cell membranes 
(7-9). Activation of these functions results from a specific cleavage by a host protease 
of a  precursor,  Fo,  to yield  the  active  F  protein  comprised  of two  disulfide-linked 
polypeptides (7-10). The cell-fusing activity of paramyxoviruses makes possible spread 
of infection from cell to adjacent cell by fusion of their plasma membranes, in addition 
to the more usual mode of dissemination of infection by released virus. The formation 
of multinucleated  giant cells by cell fusion is a  major cytopathic effect of paramyxo- 
viruses  (11,  12), and different cell types vary in their susceptibility to cell fusion (12- 
14).  It is also pertinent  to these studies that the virus-induced syncytia contain large 
amounts of viral proteins, even though little mature infectious virus may be released 
(12-14). 
Because of the biological properties of the two paramyxovirus surface glycoproteins, 
antibody-mediated  impairment  of  the  function  of either  glycoprotein  would  be 
expected  to  affect  the  spread  of  a  paramyxovirus  infection.  We  have  prepared 
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antibodies specific for each of the glycoproteins of the parainfluenza virus simian virus 
5  (SV5) 2 to study the functions of these proteins and to evaluate the effectiveness of 
antibodies to each in inhibiting the individual biological activities of the proteins and 
in preventing the initiation and spread of infection. This report describes the effects 
of these antibodies on the spread of SV5 infection in two cell types that differ in their 
susceptibility  to virus-induced  cell fusion. It will be shown that anti-HN antibodies, 
which block virus adsorption, were effective only when there was little cell fusion and 
dissemination occurred through released  progeny virions, whereas anti-F antibodies 
were capable of completely preventing the spread of infection in cells susceptible  to 
virus-induced fusion, as well as in nonfusing cells. These results, which emphasize the 
importance  of  cell-fusing  activity  in  the  spread  of  paramyxovirus  infections,  are 
discussed in relation to the requirements for effective vaccines against paramyxovirus 
infections,  the  failure of inactivated  vaccines,  and  the serious atypical  diseases  that 
may occur when individuals  immunized with inactivated  vaccines are infected with 
live virus. 
Materials and Methods 
Cells and Virus.  The Madin-Darby bovine kidney (MDBK) cells were grown in reinforced 
Eagle's minimal essential medium (REM) with 10% fetal bovine serum (6). An epithelioid clone 
of the  CV-1  line of African  green  monkey cells,  kindly provided  by  Dr.  E.  Gershey  (The 
Rockefeller  University,  New  York),  was  grown  as  described  3 in  Eagle's  minimal essential 
medium (MEM) with 10% fetal bovine serum. The growth of stocks of SV5 in MDBK cells and 
the determination of infectivity by plaque assay in MDBK or CV-1 cells have been described 
previously (6, 9).2 
Antibodies.  The preparation and characterization of antiviral glycoprotein antibodies have 
been described in detail elsewhere, z Briefly, rabbits were immunized with nonionic detergent- 
disrupted SV5 virions in complete Freund's adjuvant, and high-titer antisera (aSV5) against 
all the viral structural proteins were obtained. The virus used as immunogen was grown in the 
HKCC  line of hamster  kidney cells  to  avoid  the  possibility of cross-reaction  with  cellular 
antigens  in  experiments  in  MDBK  or  CV-1  cells,  aHN  and  aF  antisera  specific  for  the 
individual glycoproteins were prepared similarly, using as immunogens purified glycoproteins 
obtained by adsorption chromatography  on fetuin-agarose of nonionic detergent-solubilized 
viral envelope proteins.  2 The specificities of the antibodies were shown by double immunodif- 
fusion, immunoprecipitation, and the appropriate specific inhibition of viral hemagglutinating, 
neuraminidase, hemolyzing, and cell-fusing activities.  2 All experiments were done with isolated 
IgG or Fab fragments as indicated in the text. IgG was isolated from all sera by ion-exchange 
chromatography (15) on DEAE-cellulose (DE-52; Whatman, Inc., Clifton, N. J.), and stored at 
4°C  in phosphate-buffered  saline azide  (PSA; 0.05  M  sodium  phosphate,  pH  7.35, 0.15  M 
NaCI, 0.02% [wt/vol] sodium azide). Fab fragments of aHN and aF antibodies were prepared 
by digestion with papain (16)  (Worthington Biochemicals Corp., Freehold, N. J.).  Before use, 
antibodies were dialyzed against two changes of 1,000 vol of MEM or REM at 4°C, and then 
sterilized  by  uhrafiltration  through  a  Millipore filter  (type  HA;  Millipore Corp.,  Bedford, 
Mass.). 
Neutralization of the Spread of Infection.  Confluent monolayers of CV- 1 or  MDBK  cells  in 
microtest plates (No. 3034; Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, Calif.) 
were inoculated with SV5 at a multiplicity of inoculation (MOI) of 0.01  plaque-forming units 
(PFU) per cell. After a  2-h adsorption period, cells were washed with MEM or REM, and  10 
pl  of medium was  placed  in each  well.  The  medium  in duplicate plates  was  replaced  9  h 
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F[c.  1.  Cytopathic effects in SV5-infected  MDBK (a and b) or CV-1  (c and d) cells. (a) and (c), 
mock-infected cells. (b) MDBK cells 36 h p.i. (d) CV-I cells 24 h p.i. Cells were infected at an MOI 
of 1 PFU/celI. Phase-contrast  micrograph,  x  67. 
postinfection (p.i.)  with medium that contained either preimmune rabbit IgG, or anti-glyco- 
protein IgG or Fab, and incubation was continued at 37°C. Anti-glycoprotein antibodies were 
used in twofold dilutions made from 2 mg/ml stock solutions in MEM or REM. At 30-32 h, 
and again at  50-60 h  p.i., the monolayers in one plate were washed repeatedly with buffered 
saline (BS; 0.02 M  sodium phosphate, pH 7.2, 0.15 M  NaCI), and fixed with chilled (-20°C) 
ethanol for 15 min at -70°C. The plates were air dried and stored at -70°C until immunoflu- 
orescent staining was performed. 
Indirect Immunofluorescent Staining.  Fixed cell monolayers were rehydrated for 30 min at 25°C 
with BS, and after aspiration, each well received 5 #1 of preimmune rabbit IgG or aSV5 IgG, 
at a concentration of 2 mg/ml in PSA. Plates were incubated for  1 h  at 37°C in a  humidified 
chamber. After washing excess unbound IgG from the plates with BS and aspiration of BS to 
near dryness, 5/xl of fluorescein isothiocyanate-conjugated goat  (anti-rabbit IgG) IgG (FITC- 
GARIgG; fluorescein:protein molar ratio =  4.34; Antibodies, Inc., Davis, Calif.) at a  concen- 
tration of 0.5 mg/ml in PSA, was added to each well, and incubation was continued at  37°C 
for an additional hour. Unbound FITC-GARIgG was washed from each well with BS. Stained 
plates were stored in BS at 4°C in the dark until they were examined and photographed with 
a  Leitz inverted microscope (E. Leitz, Inc., Rockleigh, N. J.)  with epifluorescent excitation at 
495 nm and suppression at 525 nm. Kodak Tri-X (Eastman Kodak, Co., Rochester, N. Y.) was 
used at ASA  1,600 and developed with Diafine (Acufine, Inc., Chicago, Ill.). Exposures were 
automatically metered, and photomicrographs were taken at a  magnification of 40. 
Results 
Progression of SV5 Infection  in MDBK and CV-1  Cells.  Paramyxovirus infection may 
be propagated  by the conventional mode in which virions released  from an infected 
cell  are  disseminated  in  the  extracellular  environment  to  adsorb  to  and  penetrate 
other cells. In addition, because of their ability to cause cell fusion, paramyxoviruses 
can spread  dii'ectly to  adjacent cells by fusion of their membranes, forming syncytia 
that  can  become  very  large.  Fig.  1  shows  cytological  changes  in  two  cell  types  in 
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F~G. 2.  The spread of SV5 infection in MDBK and CV-i cells shown by immunofluoreseence 
using antivirion antibodies. Left: MDBK cells (a) 30 h, (b) 40 h, (c) 50 h, and (d) 65 h p.i. Right: 
CV-1 cells (e) 24 h, (f) 42 h, (g) 56 h, and (h) 67 h p.i. MOI, 0.01 PFU/celI. Indirect immunoflu- 
orescent staining with rabbit aSV5 IgG and FITC-GARIgG. × 67. 
amounts  of virus,  e.g.,  -600  PFU/cell  in  24-36  h  with  production  continuing  for 
several days (6,  14), and they are relatively resistant to virus-induced cell fusion. Fig. 
1 b  shows MDBK  cells 36 h  after infection; they appear somewhat larger than control 
cells (Fig. 1 a), but there are no giant cells and the monolayer is still intact. In contrast, 
SV5-infected CV-1  cells produce  ~  100  PFU/cell and  undergo extensive cell fusion, 
leading to the formation of large syncytia (Fig. 1 d) and subsequent cell death. Similar D.  C.  MERZ,  A.  SCHEID,  AND  P.  W. CHOPPIN  279 
Fro. 3.  Neutralization  of the spread of SV5 infection in CV-I cells with preimmune  (a, b), aHN 
(c, d), or aF (e, f) IgG that were added 9 h p.i. Cells were stained with rabbit aSV5 and FITC- 
GARIgG at  30  h  (a,  c,  e)  and  50  h  (b,  d,  f)  after  infection  at  an  MOI  of 0.01  PFU/celI. 
Concentrations  of antibodies used for neutralization  were: preimmune  2 mg/ml; aHN and etF, 1 
mg/rnl. × 67. 
differences in the susceptibility of different cells to SV5-induced cell fusion, and  the 
correlation  of such  differences  with  cell  survival  and  virus  production,  have  been 
described previously (3,  12-14). 
The  time-course  of  SV5  infection  in  MDBK  and  CV-1  cells,  as  detected  by 
immunofluorescent  staining with aSV5  antibody, is illustrated in  Fig.  2.  Cells were 
inoculated  with  a  low  virus  multiplicity to  give  multiple-cycle replication  and  to 
permit the observation of the development of foci of infection. In MDBK  cells (Fig. 
2a-d), single, brightly stained cells were detected 30  h  p.i., and  in the ensuing 35  h 
the  infection  was  disseminated  to  the  entire  cell  monolayer.  The  vast  majority of 
infected cells remained as single cells, and, although there were a  very few binucleate 
cells, there  was  no  evidence  of extensive cell  fusion.  There  was  no  staining  of the 
nuclei of infected cells, and this is in agreement with the previous demonstration that 
the replication of SV5 is confined to the cytoplasm (12,  13). 
In infected CV-1 cells (Fig. 2 e-h), single stained cells were detected at 24 h, and by 
42 h  there were scattered single infected cells, whereas most of the infected foci were 280  PREVENTION OF SPREAD  OF  PARAMYXOVIRUS  INFECTIONS 
Ftc. 4.  Neutralization of the spread of SV5 infection in CV-I ceils by monovalent antibodies 
added 9 h p.i. (a, b) aHN Fab; (c, d) aF Fab. Ceils were stained with aSV5 IgG and FITC-GARIgG 
at 32 h (a, c) and 58 h (b, d) after infection at an MOI of 0.0t  PFU/ee[I. otHN Fab and aF Fab 
concentrations, 1 mg/ml. X 67. 
multinucleate giant cells (Fig. 2 e), which enlarged to involve the entire monolayer by 
67  h  (Fig.  2 h).  These studies  illustrate  that  whereas  in  MDBK  cells  the infection  is 
disseminated  from cell  to cell  by released  virus  without  cell  fusion,  in  CV-1  cells  a 
major  mode  of spread  is  by  fusion  of adjacent  cells  resulting  in  the  formation  of 
enlarging syncytia. Dissemination of infection to noncontiguous cells by released virus 
can also occur in CV-1  cells. 
Neutralization of the Spread of SV5 Infection in Fusing Cells with Monospecific Antibodies 
against the Individual  Virus Glycoproteins.  The ability of antibodies against the HN or F 
glycoproteins of SV5 added after the viral adsorption period to prevent the spread of 
infection in CV-1  cells was investigated.  It was previously established 2 that  either of 
these antibodies can neutralize the infectivity of the virus if added to the virus before 
adsorption;  the  aHN  antibodies  inhibit  adsorption,  and  the  aF  antibodies  inhibit 
virus penetration that is mediated by virus-cell membrane fusion. Fig. 3 a and b  show 
the  normal  progression  of infection  in  the  presence  of preimmune  IgG,  with  large 
syncytia  as  well  as  single  infected  cells  present.  Fig.  3c  and  d  show  that  aHN 
antibodies,  although  inhibiting  the dissemination  of infection  to single cells,  do not 
prevent  the spread  of infection by cell fusion and the formation of large syncytia by 
50 h  p.i.  In contrast,  the aF antibody completely prevented  the spread  of infection, 
i.e., the infection was confined to the few individual  cells that  were initially  infected, 
and  there were no syncytia. 
These  results  are  consistent  with  the  known  activities  of the  HN  protein.  By 
preventing virus adsorption,  which  is mediated  by the HN protein, aHN  antibodies 
effectively  prevented  the  dissemination  of infection  by  released  virus,  but  did  not 
inhibit spread by cell fusion, which is mediated by the F  protein. On the other hand, 
aF  antibodies  were  capable  of completely  preventing  the  spread  of infection  by D. C.  MERZ, A. SCHEID, AND P.  W. CHOPPIN  281 
FIG. 5.  Neutralization  of the spread of SV5 infection in MDBK cells by monovalent antibodies 
added 9 h p.i. (a, b) preimmune IgG; (c, d) aHN Fab. Cells were stained with aSV5 IgG and FITC- 
GARIgG at 36 h (a, c) and 58 h (b, d) after infection at an MOI of 0.01 PFU/celI. Concentration 
of antibodies: preimmune IgG, 2 mg/ml; aHN Fab, 1 mg/ml. X 67. 
blocking the cell-fusing activity of the F protein, as well as neutralizing any released 
virus at the level of virus penetration, a step in infection which results from fusion of 
viral  and  cell  membranes  mediated  by  the  F  protein.  The  failure  of  the  c~HN 
antibodies  to  inhibit  syncytium formation  was  not  simply a  result  of the  lack  of 
sufficient antibody to neutralize the released virus, because the aHN IgG preparation 
used  contained  twice  the  neutralizing  capacity of the  aF  IgG in  a  preadsorption 
neutralization  test. 2 Furthermore,  as shown below,  the  aHN serum  was capable of 
preventing spread of infection in cells  that were resistant  to fusion. Thus the spread 
of infection in the presence of aHN antibodies was possible because of the uninhibited 
action of F protein, which was capable of causing fusion of infected ceils with adjacent 
cells,  allowing spread without the release of virus into the medium. 
It  has  been  reported  that  under  certain  conditions  virus-specific  antisera  may 
enhance the extent of cell  fusion in paramyxovirus-infected cells  (17,  18). Thus, the 
cell fusion seen in the presence of aHN IgG might  not have been only the result  of 
unimpaired  expression  of F  glycoprotein  activity,  but  also  the  result  of immune 
complex formation and consequently improved cell-fusing activity. To investigate this 
possibility,  similar  neutralization  of dissemination  experiments  were  repeated  with 
monovalent aHN  and  c~F antibodies.  It was  shown  previously that  Fab  fragments 
possessed the same activities against virions as did bivalent IgG antibodies. 2 As shown 
in Fig. 4, the presence of aHN or aF Fab in the medium after inoculation gave results 
that  were  identical  to  those  obtained  above with  IgG. aHN  Fab  (Fig.  4a  and  b) 
prevented dissemination by released virus but did not inhibit the spread of infection 
by cell  fusion,  whereas  aF  Fab  (Fig.  4c  and  d)  prevented  entirely  the  spread  of 
infection. Hence, the spread of infection by fusion of adjacent cells  in the presence of 
aHN antibody was not the result of aggregated progeny virions with increased fusion 282  PREVENTION OF SPREAD OF  PARAMYXOVIRUS INFECTIONS 
capability, but simply fusion of cells through the unrestricted action of F glycoprotein. 
Neutralization of Virus Dissemination in Nonfusing Cells with Monospecific Antibodies against 
Viral Glycoprotems.  Cell-to-cell spread of infection in nonfusing cells in the absence of 
released  infectious  virions  would  be  expected  to  be  minimal.  To  investigate  this 
question,  the  effect of antibodies  against  the  individual  viral  glycoproteins on  the 
dissemination of infection in MDBK cells was determined. As shown above (Fig.  1 b), 
extensive fusion  does  not  occur  in  SV5-infected  MDBK  cells.  Control  preimmune 
rabbit IgG failed to alter the progression of the infection  (Fig.  5 a  and b);  however, 
the  presence of either  aHN  Fab  (Fig.  5c  and  d)  or ~HN  IgG (not  shown)  in  the 
medium  after infection completely prevented  the  spread of infection.  As expected 
from the  above results  with  CV-1  cells,  both  aF  IgG and  aF  Fab  also completely 
prevented the spread of infection in MDBK ceils (not shown). Thus, in the absence 
of cell fusion, HN antibodies are capable of inhibiting the dissemination of the virus, 
and it is the ability of the F protein to cause cell fusion that allows the virus to spread 
in the presence of antibodies to the HN glycoproteins. 
Discussion 
The use of monospecific antibodies against each of the two surface glycoproteins of 
a  paramyxovirus has enabled a  better understanding of the role of these proteins in 
the initiation and propagation of infection and has demonstrated the requirement for 
antibodies to the F glycoprotein for the complete prevention of spread of paramyxo- 
virus infections. Previous studies have shown that the HN protein is required for virus 
adsorption,  and  that  the  F  protein  is  responsible  for  the  virus-induced  fusion  of 
membranes that  is essential  for virus penetration,  virus-induced  hemolysis, and the 
formation of syncytia in infected cells (7-9,  19).  In addition,  it has been shown that 
antibodies against either of the glycoproteins are capable of neutralizing the infectivity 
of the virus if the antibody interacts with the virus before it absorbs to the cell, the 
aHN antibodies by preventing virus adsorption, and the aF antibodies by inhibiting 
penetration. 2 The studies  reported  here have  illustrated  that  a  paramyxovirus can 
spread from cell  to cell by means of cell fusion without  a  requirement  for released 
infectious virus. The use of monospecific antibodies has shown that such spread is the 
result of the action of the F protein and that antibodies to this protein are required to 
prevent  spread  of infection  in  a  system  in  which  cell  fusion  can  occur,  whereas 
antibodies to the HN protein can prevent dissemination of infection through neutral- 
ization of released virus only if cell fusion does not occur. 
The requirement  for antibodies  to the  F  protein  for the  prevention  of spread of 
paramyxovirus infections has significant implications for the development of effective 
paramyxovirus vaccines,  and  may provide  an  explanation  for previous  failures  of 
inactivated vaccines and the complications encountered when certain individuals who 
received such vaccines were infected with the respective virus.  Formalin-inactivated 
vaccines and,  in a  few cases, Tween-ether-inactivated vaccines, have been prepared 
and tested for measles, mumps, parainfluenza, and respiratory syncytial (RS) viruses 
(20-36). These vaccines have proven not to be successful, even in c~ses in which they 
induced the formation of significant titers of hemagglutination-inhibiting or neutral- 
izing  antibodies,  as  determined  in  conventional  tests  in  which  virus  and  sera  are 
mixed before virus adsorption. Not only was there no effective protection with these 
vaccines, but  in  some instances,  e.g.,  with  measles and  RS  viruses,  the  illness  that D. C.  MERZ, A. SCHEID, AND P. W. CHOPPIN  283 
developed on subsequent infection was more severe than in unvaccinated individuals 
(22, 23, 25-28, 32-36). This will be discussed further below. 
Evidence that suggested an explanation for the failure of inactivated vaccines was 
obtained by Norrby and co-workers (29-31, 37), who found that formalin- or Tween- 
ether-inactivated measles and mumps vaccines induced hemagglutinating-inhibiting, 
but not hemolysis-inhibiting antibodies in humans, and that inactivated Sendai virus, 
a  murine  parainfluenza  virus,  produced  similar  results  in  rabbits.  These  workers 
suggested that  the failure of the vaccines could be related to the lack of hemolysis- 
inhibiting  antibodies,  and  that  this  lack  might  also  be  somehow  involved  in  the 
atypical measles that  occurred in  individuals receiving inactivated vaccine (30).  In 
interpreting these results with measles virus, it is pertinent that  recent studies with 
this  virus  have  indicated  that  the  protein  responsible  for  measles  virus-induced 
hemolysis  is  analogous  to  the  F  protein  of other  paramyxoviruses,  and  that  the 
hemagglutinin protein (H) of measles is analogous to the HN of  other paramyxoviruses 
except that it does not possess neuraminidase activity (38, 39). 
Our  finding of the requirement  for antibodies to the F  protein for the complete 
prevention of the spread of a  paramyxovirus infection, coupled with  the  failure of 
formalin-inactivated vaccine to stimulate the formation of antibodies to the F protein, 
provides not only an explanation for the failure of such vaccines to provide effective 
protection, but  also  additional  information  on  the  pathogenesis  of pneumonia  in 
atypical measles and the severe bronchiolitis and pneumonia that have been observed 
in some patients who were immunized with formalin-inactivated vaccines and sub- 
sequently  infected.  In  both  instances  it  has  been  suggested  that  these  syndromes 
involved  immunopathological  processes.  Buser  (32)  and  Scott  and  Bonnano  (33) 
observed local reactions in individuals who received killed-measles virus vaccine and 
later live measles virus vaccine that were suggestive of Arthus reactions, and subse- 
quent studies have supported this conclusion (34). Chanock et al. (35) found that the 
highest evidence of RS virus pneumonia occurred in infants with the highest level of 
neutralizing antibodies in their serum, consistent with an antibody-mediated patho- 
genesis of the disease, and suggested that, in the bronchiolitis occurring in children 
who had received the killed RS virus vaccine, the severity of the disease was a result 
of reaction  between  the  circulating  antibodies  elicited  by  the  vaccine  and  virus 
replicating in  the  lung because of the absence of local  immunity  (36).  Additional 
evidence suggesting that  immunopathological mechanisms may play a  role in para- 
myxovirus infections has been obtained in studies of respiratory infections of children 
(40),  cattle  (41),  and  mice  (42),  which  implicated  virus-specific immune  complex 
formation in pathogenesis, and in the finding that experimentally induced immune 
complex disease of the lung resembles viral interstitial pneumonia (43, 44). 
Correlation of our demonstration that  aF  antibodies are required to completely 
prevent the spread of paramyxovirus infections with the previously observed lack of 
aF antibodies in individuals receiving inactivated vaccines and the clinical findings 
mentioned above has led us  to suggest  a  hypothetical explanation for the atypical 
disease occurring in recipients of killed-virus vaccines that  is schematically depicted 
in Fig. 6. Some cells in the respiratory tract are infected in the initial exposure to the 
virus, and  there could perhaps be some early dissemination  by released  virus as a 
result of the absence of local immunity. The infection could undergo spread from the 
initially infected cells to adjacent cells by cell fusion because antibody to the receptor- 284  PREVENTION OF SPREAD OF PARAMYXOVIRUS  INFECTIONS 
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Fie.  6.  Schematic  representation of a hypothetical sequence of events leading to immunopathol- 
ogical injury in individuals infected with a paramyxovirus after vaccination with an inactivated 
virus vaccine that failed to stimulate antibodies to the viral F glycoprotein. 
binding protein  (HN, or H  in the case of measles)  present  as a  result of vaccination 
could not prevent the spread by fusion. It is known that paramyxoviruses can cause 
syncytium formation in  respiratory epithelium.  This  is  maximally expressed  in  the 
giant cell pneumonia that occurs in immunocompromised hosts infected with measles 
(45, 46) or parainfluenza 3 (47, 48) viruses.  As the infection spreads by cell fusion, the 
viral antigens produced in those cells,  and released virus particles neutralized by the 
c~H antibodies, would serve as secondary antigenic stimuli, resulting in a hyperimmune 
response  to  H  and  other  viral  antigens  (except  F)  for which  the  vaccination  had 
provided the primary stimulus. Recent studies have shown that the convalescent sera 
of patients with atypical measles contain high levels  of antibodies, not only to the H 
protein,  but  also  to  other  viral  proteins  (49)  (W.  W.  Hall,  M.  H.  Kaplan,  P.  W. 
Choppin. Unpublished observations.). With the infected syncytia presenting the viral 
antigens, immune complex formation could occur in the lungs, resulting in comple- 
ment activation and inflammation, i.e., an Arthus-like reaction. Alternatively, K cells 
could  be  recruited  to  antibody-coated syncytia  (50-53),  resulting  in  an  antibody- 
dependent cellular cytotoxic reaction. This sequence of events could explain atypical 
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It is not yet clear which RS viral protein is responsible for cell fusion, but there can 
be little doubt that a  viral protein  is involved, and it would appear likely from the 
experience with measles, mumps, and parainfluenza viruses that formalin treatment 
could inactivate the antigenicity of the putative RS virus fusion protein as well. 
The  studies  reported  here  have  clearly  demonstrated  that  an  effective  vaccine 
against paramyxoviruses must elicit  antibodies to the F  protein.  Live virus vaccines 
would be expected to do so, and much effort is being devoted to the development of 
live virus vaccines for several of these viruses for which vaccines are not now available, 
including  RS  virus  (54).  However,  there  are factors that  argue  for development of 
inactivated vaccines as well, e.g., the availability of a vaccine for use in immunocom- 
promised  individuals,  and  the  theoretical  possibility  of  persistent  infection  after 
vaccination, a  problem that deserves particular consideration with paramyxoviruses 
because of the ability of many of them to cause persistent infections (1, 2). The failure 
of previous formalin-treated vaccines against several paramyxoviruses has understand- 
ably dampened enthusiasr~, for inactivated paramyxovirus-vaccines; however, because 
these vaccines were deficient  in eliciting aF antibodies,  and  it  is now clear that  aF 
antibodies are essential for effective protection, this situation should be reevaluated. 
Vaccines consisting of isolated purified viral surface proteins, not requiring formalin 
treatment, could represent important additions to our immunization armamentarium 
against these important diseases. 
Summary 
The effects of monospecific antibodies to the viral glycoprotein with hemagglutin- 
ating and neuraminidase activity (HN)  and the viral glycoprotein with membrane- 
fusing  activity  (F)  of the  paramyxovirus  simian  virus  5  (SV5)  on  the  spread  of 
infection in two cell types have been investigated. In CV-1 cells, infection can spread 
by either released progeny virus adsorbing to and infecting other cells, or by fusion of 
an infected cell with  an adjacent  cell as a  result  of the cell-fusing activity of the F 
glycoprotein. In these cells, antibodies specific for the HN glycoprotein prevented the 
dissemination of infection by released infectious virus, but spread by cell fusion was 
not  inhibited.  Antibodies  to the F  glycoprotein completely prevented the spread of 
infection  in  these  cells.  In  Madin-Darby  bovine  kidney  cells,  which  are  relatively 
resistant to SV5-induced fusion, antibodies to either the HN or F glycoproteins were 
capable of preventing the dissemination of infection. 
These  results  indicate  that  effective  immunological  prevention  of the  spread  of 
paramyxovirus infection  requires  the  presence  of antibodies  that  inactivate  the  F 
glycoprotein. This requirement for anti-F antibodies has obvious implications for the 
design of effective paramyxovirus vaccines and provides an explanation for previous 
failures of formalin-inactivated paramyxovirus vaccines as well as additional  insight 
into the possible immunopathological mechanisms involved in the atypical and severe 
infections that have occurred in individuals who received inactivated paramyxovirus 
vaccines and were subsequently infected by the virus. 
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